Table 3.
Outcomes following focal salvage HDR brachytherapy.
| Outcome | Number (%) |
|---|---|
| Median (range) nadir PSA | 0.27 (0.01–2.8) |
| Further disease relapse | |
| None | 25 (58%) |
| Biochemical progression | 9 (21%) |
| Local recurrence | 6 (14%) |
| Local and nodal recurrence | 1 (2%) |
| Distant metastatic disease | 1 (2%) |
| Median (range) PSA at time of relapse | 2.7 (1.83–16.5) |
| Further treatments received | |
| None | 12 (67% of 18 patients with relapse) |
| ADT/maximum androgen blockade | 4 (22%) |
| Enzalutamide/abiraterone | 2 (11%) |
| Chemotherapy | 1 (6%) |
| Radionuclide therapy | 1 (6%) |